Thaison Consulting is led by Ching Thai, who has 14 years intense experience in the pharmaceutical industry in Clinical Pharmacology, Pharmacometrics and pre-clinical DMPK, with an MSc in Model Informed Drug Development from the University of Manchester.

The main therapeutic areas being neuroscience and oncology. Ching has successful supported the submission and approval of EPIDIOLEX across different regions the world including US, UK, EU, Switzerland, Australia, Japan and Taiwan, for 3 rare forms of epilepsy. In addition, Ching has also supported the submission of REZZAYO in China for rare infection disease.

Leveraging his expertise in pharmacokinetics and pharmacometrics, Ching has led the strategy for multiple paediatric drug development programs.

Translational therapy is also another area of expertise, having conducted multiple Phase 1 clinical studies, particularly designing First-in-human trials using non-clinical data to predict human exposure. Which has lead to the discovery of unique oral cannabinoid formulations (Patent WO2021123804A1) 

His prior experience in the laboratory performing ADME screening assays, combined with modelling expertise enhances deep mechanistic understanding of building PBPK models that has been well-informed for drug development.

Education has throughout been in the UK, but has cultural and linguistic skills in Chinese and Japanese,  allowing him to work effectively and forming close relationships in global teams between US, UK, EU, Japan and China. Experience is not limited to mid to large pharmaceutical companies such as GlaxoSmithKline, Mundipharma and Jazz Pharmaceuticals, but also has worked with multiple start-up biotech companies.

A list of Publications can be found here and gives an overview of Ching's broad experience across the industry.

For larger complex project, Thaison Consulting has a team of highly experienced Data Scientist and Pharmacometricians that can support your programs.